Earnings summaries and quarterly performance for NEONC TECHNOLOGIES HOLDINGS.
Research analysts covering NEONC TECHNOLOGIES HOLDINGS.
Recent press releases and 8-K filings for NTHI.
NeOnc Technologies Announces Positive Preclinical Findings for NEO100 and a $1 Million Stock Sale
NTHI
New Projects/Investments
Equity Issuance
- NeOnc Technologies (NTHI) announced new preclinical findings on December 1, 2025, demonstrating that ultrasound enhances the therapeutic potency of NEO100 in treating various primary and metastatic brain tumors.
- The AI-driven research identified NEO100 as a leading sonodynamic therapy agent, with validation studies supporting its advancement into future clinical trials when combined with focused ultrasound.
- On December 1, 2025, the company entered into a Securities Purchase Agreement to sell 111,732 shares of common stock at $8.95 per share to an investor, raising approximately $1 million.
- The net proceeds from this stock sale are intended for working capital.
1 day ago
NeOnc Technologies Holdings Reports Q3 2025 Results and Clinical Milestones
NTHI
Earnings
New Projects/Investments
Management Change
- NeOnc Technologies Holdings, Inc. reported a net loss of $8.6 million or $0.45 per diluted share for Q3 2025, compared to a net loss of $2.2 million or $0.12 per diluted share in Q3 2024.
- The company announced positive Phase 2a clinical results for NEO100 in recurrent brain cancer, showing a 21% response rate and 33% of patients remaining alive ≥18 months. Top-line data for NEO100-01 is anticipated in May 2026.
- The FDA authorized the Phase II Clinical Trial of NEO212, with the final patient cohort in Phase I expected to complete dosing in Q4 2025.
- NeOnc secured $2.5 million in STTR grants from NIH and progressed a $50 million strategic partnership with Quazar Investment through its NuroMENA subsidiary.
Nov 14, 2025, 9:46 PM
NeOnc Technologies Reports Positive Clinical Results for NEO100 in Brain Cancer Trial
NTHI
New Projects/Investments
- NeOnc Technologies Holdings, Inc. (NTHI) announced updated clinical results for its investigational intranasal agent, NEO100, in a cohort of 24 patients with recurrent WHO Grade III/IV IDH1-mutant astrocytoma.
- The study showed a significant radiographic response in 21% of patients (5 of 24), exceeding the <8% typically observed with salvage therapies.
- 44% of patients achieved six-month progression-free survival (PFS-6), outperforming historical benchmarks of 21–31% for IDH1-mutant recurrent high-grade gliomas.
- 33% of patients (8 of 24) demonstrated durable survival ≥18 months after NEO100 initiation, with a median overall survival of 88 months for these long-term survivors, and no significant toxicity was reported.
Nov 12, 2025, 10:06 PM
NeOnc Technologies to Host Investor Conference Call for Clinical Trial Data Updates
NTHI
New Projects/Investments
- NeOnc Technologies Holdings, Inc. (NTHI) announced an investor conference call and webcast scheduled for Wednesday, November 12, 2025, at 9:00 a.m. Eastern Time.
- The call will provide data updates from the ongoing Phase 1/2a NEO100-1 clinical trial and compassionate use program.
- The updates will highlight MRI-based radiographic response data, progression-free survival (PFS), and overall survival (OS) trends for NEO100 in patients with recurrent high-grade malignant glioma.
- NeOnc's NEO100™ and NEO212™ therapeutics are currently in Phase II human clinical trials and have FDA Fast-Track and Investigational New Drug (IND) status.
Nov 10, 2025, 10:01 PM
NeOnc Technologies Holdings, Inc. Appoints New CEO and Grants Restricted Stock Award
NTHI
CEO Change
Management Change
Executive Compensation
- NeOnc Technologies Holdings, Inc. appointed Amir Heshmatpour as its new Chief Executive Officer, effective October 31, 2025, with Dr. Thomas Chen transitioning to Chief Medical Officer and Chief Scientific Officer.
- Mr. Heshmatpour will continue to serve as President and Executive Chairman.
- In connection with his appointment, Mr. Heshmatpour was granted 1,200,000 shares of restricted stock on November 6, 2025.
- The restricted stock will vest with 600,000 shares on January 2, 2026, and the remaining 600,000 shares in twelve equal monthly installments starting February 1, 2026. His initial compensation includes a $1 per year salary until a formal employment agreement is finalized.
Nov 6, 2025, 10:00 PM
NTHI Subsidiary NuroMENA Appoints His Highness Sheikh Nahyan bin Zayed Al Nahyan as Executive Chairman
NTHI
Management Change
New Projects/Investments
Board Change
- NeOnc Technologies Holdings, Inc. (NTHI) announced that His Highness Sheikh Nahyan bin Zayed Al Nahyan will assume the role of Executive Chairman of NuroMENA Holdings Ltd., its Middle East subsidiary, effective October 28, 2025.
- This appointment represents a strategic alliance and direct involvement in a biotechnology venture focused on brain cancer treatment, with the backing of a major sovereign wealth fund expected to fundamentally change the company's trajectory.
- Amir Heshmatpour, current Executive Chairman and President of NeOnc Technologies, will transition to Vice Chairman of NuroMENA.
Oct 30, 2025, 9:00 PM
NeOnc Technologies Holdings and Quazar Investment Set to Close $50 Million Strategic Partnership
NTHI
New Projects/Investments
M&A
- NeOnc Technologies Holdings, Inc. (NTHI) announced that its $50 million strategic partnership with Quazar Investment is mandated to close no later than October 23, 2025.
- This closing is contingent upon the receipt of all necessary tax identification and regulatory approvals from the United Arab Emirates (UAE), which have now been finalized.
- The partnership, centered around the Abu Dhabi-based operating subsidiary NuroCure, aims to launch and scale clinical trials, regulatory filings, and infrastructure development across the UAE and the broader Middle East and North Africa (MENA) region.
- The funds will accelerate the development of NeOnc’s therapeutic pipeline, including its NEO100 and NEO212 clinical programs, with $15 million specifically allocated for Phase 2B clinical trials and infrastructure development in the UAE and MENA.
- This transaction will enable NeOnc to initiate four upcoming clinical trials: NEO100-01, NEO100-02, NEO212 (all advancing into Phase 2a/2b), and NEO100-03 (its first pediatric brain cancer program entering Phase 1).
Oct 10, 2025, 9:00 PM
NeOnc Technologies receives FDA authorization for Phase II clinical trial of NEO212
NTHI
Product Launch
New Projects/Investments
- NeOnc Technologies Holdings, Inc. (NTHI) received FDA authorization on September 10, 2025, to proceed with Phase IIa/IIb of its NEO212-01 clinical trial.
- This authorization follows the successful completion of the Phase I dose-escalation study, which demonstrated NEO212 could be safely administered.
- NEO212 is a first-in-class oral chemical conjugated chemotherapy candidate for brain cancer, which NeOnc believes has the potential to replace Temozolomide (TMZ) as the future standard of care.
- Patient enrollment for the Phase II trial is expected to begin before the end of 2025.
Sep 11, 2025, 9:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more